Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Open accessPublished version of a preprint
The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
Abstract Malignant pleural mesothelioma (MPM) is a highly lethal cancer of the lining of the chest cavity. To expand our understanding of MPM, we conducted a comprehensive integrated genomic study, including the most detailed analysis of BAP1 alterations to date. We identified histology-independent molecular prognostic subsets, and defined a novel genomic subtype with TP53 and SETDB1 mutations and extensive loss of heterozygosity. We also report strong expression of the immune-checkpoint gene VISTA in epithelioid MPM, strikingly higher than in other solid cancers, with implications for the immune response to MPM and for its immunotherapy. Our findings highlight new avenues for further investigation of MPM biology and novel therapeutic options. Significance: Through a comprehensive integrated genomic study of 74 MPMs, we provide a deeper understanding of histology-independent determinants of aggressive behavior, define a novel genomic subtype with TP53 and SETDB1 mutations and extensive loss of heterozygosity, and discovered strong expression of the immune-checkpoint gene VISTA in epithelioid MPM. See related commentary by Aggarwal and Albelda, p. 1508. This article is highlighted in the In This Issue feature, p. 1494
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, a study that explored 74 mesothelioma tumors using a genomic analysis identified TGF-β1 mRNA expression as being correlated with the worst patient prognoses [40].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422
Absolute quantification of somatic DNA alterations in human cancer
Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,053
Self-citationThe Life History of 21 Breast Cancers
Nik-Zainal, S., Van Loo, P., Wedge, D. C., Alexandrov, L. B., Greenman, C. D., Lau, K. W., Raine, K., Jones, D., Marshall, J., Ramakrishna, M., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.023 · Cited by 1,443 · cited 1×
“Since MPM with evidence of GNH have typically undergone a genome-doubling event, we were able to assess the timing of this relative to point mutations (30,31).”
BackgroundSelf-citationSomatic mutation in cancer and normal cells
Martincorena, I., & Campbell, P. J. (2015) · Science · doi:10.1126/science.aab4082 · Cited by 1,396 · cited 1×
“This places MPM at the low end of somatic mutation burden among cancers (8).”
BackgroundSelf-citationShen, R., & Seshan, V. E. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw520 · Cited by 1,258
Self-citationBroz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.007 · Cited by 1,207
Clock-like mutational processes in human somatic cells
Alexandrov, L. B., Jones, P. H., Wedge, D. C., Sale, J. E., Campbell, P. J., Nik-Zainal, S., & Stratton, M. R. (2015) · Nature Genetics · doi:10.1038/ng.3441 · Cited by 1,058
Self-citationBueno, R., Stawiski, E. W., Goldstein, L. D., Durinck, S., De Rienzo, A., Modrusan, Z., Gnad, F., Nguyen, T. T., Jaiswal, B. S., Chirieac, L. R., et al. (2016) · Nature Genetics · doi:10.1038/ng.3520 · Cited by 919
Self-citationShen, R., Olshen, A. B., & Ladanyi, M. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp543 · Cited by 849 · cited 1×
“To find out whether multi-platform molecular profiling might provide additional resolution to define prognostic subsets of MPM, we performed integrative clustering across multiple assay platforms using two algorithms: iCluster (32) and PARADIGM (33).”
MethodSelf-citationVaske, C. J., Benz, S. C., Sanborn, J. Z., Earl, D., Szeto, C., Zhu, J., Haussler, D., & Stuart, J. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq182 · Cited by 786
Self-citation
Cited by
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552
Self-citationIntercellular interaction dictates cancer cell ferroptosis via NF2–YAP signalling
Wu, J., Minikes, A. M., Gao, M., Bian, H., Li, Y., Stockwell, B. R., Chen, Z.-N., & Jiang, X. (2019) · Nature · doi:10.1038/s41586-019-1426-6 · Cited by 1,110
Schürch, C. M., Bhate, S. S., Barlow, G. L., Phillips, D. J., Noti, L., Zlobec, I., Chu, P., Black, S., Demeter, J., McIlwain, D. R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.005 · Cited by 1,064
Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine
Dey, A., Varelas, X., & Guan, K.-L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0070-z · Cited by 860
The Hippo signalling pathway and its implications in human health and diseases
Fu, M., Hu, Y., Lan, T., Guan, K.-L., Luo, T., & Luo, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01191-9 · Cited by 742
Deep learning-based classification of mesothelioma improves prediction of patient outcome
Courtiol, P., Maussion, C., Moarii, M., Pronier, E., Pilcer, S., Sefta, M., Manceron, P., Toldo, S., Zaslavskiy, M., Le Stang, N., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0583-3 · Cited by 544
Self-citationThe application of Ferroptosis in diseases
Qiu, Y., Cao, Y., Cao, W., Jia, Y., & Lu, N. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104919 · Cited by 415
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
Carbone, M., Adusumilli, P. S., Alexander, H. R., Baas, P., Bardelli, F., Bononi, A., Bueno, R., Felley‐Bosco, E., Galateau‐Salle, F., Jablons, D., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21572 · Cited by 335
Self-citationThe Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer
Cunningham, R., & Hansen, C. G. (2022) · Clinical Science · doi:10.1042/cs20201474 · Cited by 326
Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer
Carbone, M., Harbour, J. W., Brugarolas, J., Bononi, A., Pagano, I., Dey, A., Krausz, T., Pass, H. I., Yang, H., & Gaudino, G. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1220 · Cited by 287
Self-citationImmune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
Wang, Y., Zhang, H., Liu, C., Wang, Z., Wu, W., Zhang, N., Zhang, L., Hu, J., Luo, P., Zhang, J., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01325-0 · Cited by 257
Self-citationPopat, S., Baas, P., Faivre-Finn, C., Girard, N., Nicholson, A. G., Nowak, A. K., Opitz, I., Scherpereel, A., & Reck, M. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2021.11.005 · Cited by 232
VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy
Yuan, L., Tatineni, J., Mahoney, K. M., & Freeman, G. J. (2021) · Trends in Immunology · doi:10.1016/j.it.2020.12.008 · Cited by 225
The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification
Sauter, J. L., Dacic, S., Galateau-Salle, F., Attanoos, R. L., Butnor, K. J., Churg, A., Husain, A. N., Kadota, K., Khoor, A., Nicholson, A. G., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.12.014 · Cited by 199
Self-citationBlum, Y., Meiller, C., Quetel, L., Elarouci, N., Ayadi, M., Tashtanbaeva, D., Armenoult, L., Montagne, F., Tranchant, R., Renier, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09307-6 · Cited by 198
Immunogenomic Landscape of Hematological Malignancies
Dufva, O., Pölönen, P., Brück, O., Keränen, M. A. I., Klievink, J., Mehtonen, J., Huuhtanen, J., Kumar, A., Malani, D., Siitonen, S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.002 · Cited by 190
Perspectives on the Treatment of Malignant Pleural Mesothelioma
Janes, S. M., Alrifai, D., & Fennell, D. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmra1912719 · Cited by 186
Muthalagu, N., Monteverde, T., Raffo-Iraolagoitia, X., Wiesheu, R., Whyte, D., Hedley, A., Laing, S., Kruspig, B., Upstill-Goddard, R., Shaw, R., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0620 · Cited by 182
Roles and mechanisms of BAP1 deubiquitinase in tumor suppression
Masclef, L., Ahmed, O., Estavoyer, B., Larrivée, B., Labrecque, N., Nijnik, A., & Affar, E. B. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00709-4 · Cited by 181
Nicholson, A. G., Sauter, J. L., Nowak, A. K., Kindler, H. L., Gill, R. R., Remy-Jardin, M., Armato, S. G., Fernandez-Cuesta, L., Bueno, R., Alcala, N., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.08.2506 · Cited by 168
Self-citationHassan, R., Morrow, B., Thomas, A., Walsh, T., Lee, M. K., Gulsuner, S., Gadiraju, M., Panou, V., Gao, S., Mian, I., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821510116 · Cited by 158
Self-citationZauderer, M. G., Szlosarek, P. W., Moulec, S. L., Popat, S., Taylor, P., Planchard, D., Scherpereel, A., Koczywas, M., Forster, M. D., Cameron, R. B., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00277-7 · Cited by 158
Self-citationBAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma
Shrestha, R., Nabavi, N., Lin, Y.-Y., Mo, F., Anderson, S., Volik, S., Adomat, H. H., Lin, D., Xue, H., Dong, X., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0620-3 · Cited by 147
Forde, P. M., Anagnostou, V., Sun, Z., Dahlberg, S. E., Kindler, H. L., Niknafs, N., Purcell, T., Santana-Dávila, R., Dudek, A. Z., Borghaei, H., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01541-0 · Cited by 147
Self-citationPersistent mutation burden drives sustained anti-tumor immune responses
Niknafs, N., Balan, A., Cherry, C., Hummelink, K., Monkhorst, K., Shao, X. M., Belcaid, Z., Marrone, K. A., Murray, J., Smith, K. N., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02163-w · Cited by 145
Self-citationSchürch, C. M., Bhate, S. S., Barlow, G. L., Phillips, D. J., Noti, L., Zlobec, I., Chu, P., Black, S., Demeter, J., McIlwain, D. R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.021 · Cited by 142
An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin
Bellizzi, A. M. (2020) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000256 · Cited by 139
Genomic landscape of pleural and peritoneal mesothelioma tumours
Hiltbrunner, S., Fleischmann, Z., Sokol, E. S., Zoche, M., Felley‐Bosco, E., & Fontecedro, A. C. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01979-0 · Cited by 136
Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment
Zhang, M., Luo, J., Sun, Q., Harber, J., Dawson, A. G., Nakas, A., Busacca, S., Sharkey, A. J., Waller, D. A., Sheaff, M. T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21798-w · Cited by 132
Self-citationMalignant mesothelioma in situ: morphologic features and clinical outcome
Churg, A., Galateau-Sallé, F., Roden, A. C., Attanoos, R. L., von der Thüsen, J. H., Tsao, M., Chang, N., de Perrot, M. E., & Đačić, S. (2019) · Modern Pathology · doi:10.1038/s41379-019-0347-0 · Cited by 128
Self-citationQuetel, L., Meiller, C., Assié, J., Blum, Y., Imbeaud, S., Montagne, F., Tranchant, R., Wolf, J. D., Caruso, S., Copin, M., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12651 · Cited by 123
Fennell, D. A., King, A., Mohammed, S., Branson, A., Brookes, C. L., Darlison, L., Dawson, A. G., Gaba, A., Hutka, M., Morgan, B., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30390-8 · Cited by 122
Tsao, A. S., Lindwasser, O. W., Adjei, A. A., Adusumilli, P. S., Beyers, M. L., Blumenthal, G. M., Bueno, R., Burt, B. M., Carbone, M., Dahlberg, S. E., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.2036 · Cited by 120
Self-citationHistone Methyltransferase SETDB1: A Common Denominator of Tumorigenesis with Therapeutic Potential
Strepkos, D., Markouli, M., Κλώνου, Α., Papavassiliou, A. G., & Piperi, C. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2906 · Cited by 116
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial
Yap, T. A., Kwiatkowski, D. J., Dagogo‐Jack, I., Offin, M. D., Zauderer, M. G., Kratzke, R. A., Desai, J., Body, A. L., Millward, M., Tolcher, A. W., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-04029-3 · Cited by 115
Self-citationPleural mesothelioma classification—update and challenges
Đačić, S. (2021) · Modern Pathology · doi:10.1038/s41379-021-00895-7 · Cited by 108
Muller, S., Victoria Lai, W., Adusumilli, P. S., Desmeules, P., Frosina, D., Jungbluth, A., Ni, A., Eguchi, T., Travis, W. D., Ladanyi, M., et al. (2020) · Modern Pathology · doi:10.1038/s41379-019-0364-z · Cited by 106
Self-citationMangiante, L., Alcala, N., Sexton‐Oates, A., Genova, A. D., González-Pérez, A., Khandekar, A., Bergstrom, E. N., Kim, J., Liu, X., Blázquez‐Encinas, R., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01321-1 · Cited by 103
Self-citationFerroptosis in life: To be or not to be
Xu, L., Liu, Y., Chen, X., Zhong, H., & Wang, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114241 · Cited by 102
Molecular Pathology of Lung Cancer
Saller, J. J., & Boyle, T. A. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037812 · Cited by 98
Husain, A. N., Chapel, D. B., Attanoos, R. L., Beasley, M. B., Brčić, L., Butnor, K. J., Chirieac, L. R., Churg, A., Đačić, S., Galateau-Sallé, F., et al. (2024) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2023-0304-ra · Cited by 97
Self-citationFennell, D. A., King, A., Mohammed, S. B., Greystoke, A., Anthony, S., Poile, C., Nusrat, N., Scotland, M., Bhundia, V., Branson, A., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00062-6 · Cited by 96
Stewart, C. A., Gay, C. M., Ramkumar, K., Cargill, K. R., Cardnell, R. J., Nilsson, M. B., Heeke, S., Park, E. M., Kundu, S. T., Diao, L., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.002 · Cited by 91
Self-citationPredicting master transcription factors from pan-cancer expression data
Reddy, J., Fonseca, M. A., Corona, R. I., Nameki, R. A., Dezem, F. S., Klein, I. A., Chang, H. S. Y., Chaves‐Moreira, D., Afeyan, L. K., Malta, T. M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf6123 · Cited by 88
New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options
Tsao, A. S., Pass, H. I., Rimner, A., & Mansfield, A. S. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01567 · Cited by 86
Self-citationComputational immunogenomic approaches to predict response to cancer immunotherapies
Addala, V., Newell, F., Pearson, J. V., Redwood, A., Robinson, B. W. S., Creaney, J., & Waddell, N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00830-6 · Cited by 85
Self-citationDNA double-strand break–capturing nuclear envelope tubules drive DNA repair
Shokrollahi, M., Stanić, M., Hundal, A. K., Chan, J. N. Y., Urman, D., Jordan, C. A., Hakem, A., Espín, R., Hao, J., Krishnan, R., et al. (2024) · Nature Structural & Molecular Biology · doi:10.1038/s41594-024-01286-7 · Cited by 82
Treatment of Pleural Mesothelioma: ASCO Guideline Update
Kindler, H. L., Ismaila, N., Bazhenova, L. A., Chu, Q. S.-C., Churpek, J. E., Dagogo‐Jack, I., Bryan, D. S., Drazer, M. W., Forde, P. M., Husain, A. N., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02425 · Cited by 82
Self-citationMeiller, C., Montagne, F., Hirsch, T. Z., Caruso, S., Wolf, J. D., Bayard, Q., Assié, J., Meunier, L., Blum, Y., Quetel, L., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00931-w · Cited by 80
Self-citationChapel, D. B., Hornick, J. L., Barlow, J. S., Bueno, R., & Sholl, L. M. (2022) · Modern Pathology · doi:10.1038/s41379-022-01081-z · Cited by 80
Self-citationCurrent Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion
Mitra, A., Kumar, A., Amdare, N. P., & Pathak, R. (2024) · Biology · doi:10.3390/biology13050307 · Cited by 80
Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions
Alcala, N., Mangiante, L., Le-Stang, N., Gustafson, C. E., Boyault, S., Damiola, F., Alcala, K., Brevet, M., Thivolet-Bejui, F., Blanc-Fournier, C., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.09.003 · Cited by 77
Self-citationA scoping review and proposed workflow for multi-omic rare disease research
Kerr, K., McAneney, H., Smyth, L. J., Bailie, C., McKee, S. A., & McKnight, A. J. (2020) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01376-x · Cited by 77
Update on biology and management of mesothelioma
Asciak, R., George, V., & Rahman, N. M. (2021) · European Respiratory Review · doi:10.1183/16000617.0226-2020 · Cited by 75
Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
Ladanyi, M., Sánchez-Vega, F., & Zauderer, M. G. (2019) · Genome Medicine · doi:10.1186/s13073-019-0631-0 · Cited by 74
Self-citationKindler, H. L., Novello, S., Bearz, A., Ceresoli, G. L., Aerts, J. G. J. V., Spicer, J. F., Taylor, P., Nackaerts, K., Greystoke, A., Jennens, R. R., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00061-4 · Cited by 73
Self-citationLouw, A., Panou, V., Szejniuk, W. M., Meristoudis, C., Chai, S. M., Vliet, C. V., Lee, G., Dick, I. M., Firth, T., Lynggård, L. A., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.04.008 · Cited by 73
Self-citationMachine learning analysis of TCGA cancer data
Liñares-Blanco, J., Pazos, A., & Fernandez-Lozano, C. (2021) · PeerJ Computer Science · doi:10.7717/peerj-cs.584 · Cited by 72
MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial
Gounder, M. M., Johnson, M. L., Heist, R. S., Shapiro, G. I., Postel-Vinay, S. C., Wilson, F. H., Garralda, E., Wulf, G. M., Almon, C., Nabhan, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55316-5 · Cited by 72
Malignant pleural mesothelioma: an update
Hajj, G. N. M., Cavarson, C. H., Pinto, C. A. L., Venturi, G., Navarro, J. R., & de Lima, V. C. C. (2021) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20210129 · Cited by 71
Sathyanarayanan, A., Gupta, R., Thompson, E. W., Nyholt, D. R., Bauer, D. C., & Nagaraj, S. H. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbz121 · Cited by 70
Self-citationNew Insights into YAP/TAZ-TEAD-Mediated Gene Regulation and Biological Processes in Cancer
Zhao, Y., Sheldon, M., Sun, Y., & Ma, L. (2023) · Cancers · doi:10.3390/cancers15235497 · Cited by 68
Kukuyan, A.-M., Sementino, E., Kadariya, Y., Menges, C. W., Cheung, M., Tan, Y., Cai, K. Q., Slifker, M. J., Peri, S., Klein–Szanto, A. J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-4093 · Cited by 67
Genome Sequencing during a Patient’s Journey through Cancer
Nangalia, J., & Campbell, P. J. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1910138 · Cited by 66
Self-citationVISTA-mediated immune evasion in cancer
Zhang, R. J., & Kim, T. K. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01336-6 · Cited by 66
Galateau Salle, F., Le Stang, N., Tirode, F., Courtiol, P., Nicholson, A. G., Tsao, M.-S., Tazelaar, H. D., Churg, A., Dacic, S., Roggli, V., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.025 · Cited by 65
Self-citationImmunotherapy approaches for malignant pleural mesothelioma
Fennell, D. A., Dulloo, S., & Harber, J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00649-7 · Cited by 65
VISTA expression and patient selection for immune-based anticancer therapy
Martin, A. S., Molloy, M., Ugolkov, A. V., Roemeling, R. W. V., Noelle, R. J., Lewis, L. D., Johnson, M. L., Radvanyi, L. G., & Martell, R. E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1086102 · Cited by 64
The Molecular Basis of Malignant Pleural Mesothelioma
Wadowski, B. J., Rienzo, A. D., & Bueno, R. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.08.005 · Cited by 63
Self-citationCreaney, J., Patch, A., Addala, V., Sneddon, S., Nones, K., Dick, I. M., Lee, G., Newell, F., Rouse, E. J., Naeini, M. M., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01060-8 · Cited by 63
Self-citationTumor Immune Microenvironment and Genetic Alterations in Mesothelioma
Hiltbrunner, S., Mannarino, L., Kirschner, M. B., Opitz, I., Rigutto, A., Laure, A., Lia, M., Nozza, P., Maconi, A., Marchini, S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.660039 · Cited by 62
Molecular characterization of diffuse malignant peritoneal mesothelioma
Hung, Y. P., Dong, F., Torre, M., Crum, C. P., Bueno, R., & Chirieac, L. R. (2020) · Modern Pathology · doi:10.1038/s41379-020-0588-y · Cited by 60
Self-citationThe Separation of Benign and Malignant Mesothelial Proliferations: New Markers and How to Use Them
Churg, A., & Naso, J. R. (2020) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001565 · Cited by 59
Immunotherapy for Mesothelioma: A Critical Review of Current Clinical Trials and Future Perspectives
Gray, S. G., & Mutti, L. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.11.23 · Cited by 58
“23 checkpoint gene which was first reported as having strong expression in epithelioid MPM, above and beyond that seen in other solid cancers, with obvious implications for the immune response to MPM and for its immunotherapy (60).”
BackgroundSaha, N., & Muntean, A. G. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188498 · Cited by 56
Chapel, D. B., Dubuc, A. M., Hornick, J. L., & Sholl, L. M. (2021) · Histopathology · doi:10.1111/his.14324 · Cited by 55
Structure, Activity and Function of the SETDB1 Protein Methyltransferase
Markouli, M., Strepkos, D., & Piperi, C. (2021) · Life · doi:10.3390/life11080817 · Cited by 55
Molecular Characterization of Peritoneal Mesotheliomas
Offin, M. D., Yang, S., Egger, J. V., Jayakumaran, G., Spencer, R. S., Lopardo, J., Nash, G. M., Cercek, A., Travis, W. D., Kris, M. G., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.09.012 · Cited by 55
Self-citationShort Review: Genomic Alterations in Hürthle Cell Carcinoma
Ganly, I., & McFadden, D. G. (2019) · Thyroid · doi:10.1089/thy.2019.0088 · Cited by 54
Immunogenomic Landscape of Hematological Malignancies
Dufva, O., Pölönen, P., Brück, O. E., Keränen, M. A. I., Klievink, J., Mehtonen, J., Huuhtanen, J., Kumar, A., Malani, D., Siitonen, S. M., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.019 · Cited by 54
Elliott, D. R. F., & Jones, K. D. (2019) · Surgical pathology clinics · doi:10.1016/j.path.2019.10.001 · Cited by 52
Harber, J., Kamata, T., Pritchard, C. A., & Fennell, D. A. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003032 · Cited by 51
Moutafi, M. K., Molero-Abraham, M., Martínez-Morilla, S., Baena, J., Vathiotis, I. A., Gavrielatou, N., Castro‐Labrador, L., Ponce, G. R. D. G., Adradas, V., Orive, D., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004757 · Cited by 50
Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice
Badhai, J., Pandey, G. K., Song, J.-Y., Krijgsman, O., Bhaskaran, R., Chandrasekaran, G., Kwon, M.-C., Bombardelli, L., Monkhorst, K., Grasso, C., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191257 · Cited by 49
Use of histone methyltransferase inhibitors in cancer treatment: A systematic review
Marzochi, L. L., Cuzziol, C. I., Filho, C., dos Santos, J. A., Castanhole-Nunes, M. M. U., Pavarino, É. C., Guerra, E. N. S., & Goloni‐Bertollo, E. M. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175590 · Cited by 48
Inoue, S., Tsunoda, T., Riku, M., Ito, H., Inoko, A., Murakami, H., Ebi, M., Ogasawara, N., Pastan, I. H., Kasugai, K., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11290 · Cited by 48
Fennell, D. A., Sekido, Y., Baas, P., Husain, A. N., Fontecedro, A. C., Lim, E. K. S., Opitz, I., Simone, C. B., Brims, F., & Wong, M. C. S. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00640-3 · Cited by 47
Self-citationWhen the Diagnosis of Mesothelioma Challenges Textbooks and Guidelines
Rossi, G., Davoli, F., Poletti, V. E., Cavazza, A., & Lococo, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112434 · Cited by 47
The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models
Blanquart, C., Jaurand, M., & Jean, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00388 · Cited by 46
The pathogenesis of mesothelioma is driven by a dysregulated translatome
Grosso, S., Marini, A., Gyurászová, K., Voorde, J. V., Sfakianos, A., Garland, G. D., Rubio, A., Mordue, R., Chernova, T., Morone, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25173-7 · Cited by 46
Dagogo‐Jack, I., Madison, R. W., Lennerz, J. K., Chen, K., Hopkins, J. F., Schrock, A. B., Ritterhouse, L. L., Lester, A., Wharton, K. A., Mino-Kenudson, M. A., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00422 · Cited by 46
Ito, F., Yanatori, I., Maeda, Y., Nimura, K., Ito, S., Hirayama, T., Nagasawa, H., Kohyama, N., Okazaki, Y., Akatsuka, S., et al. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101616 · Cited by 45
Shrestha, R., Nabavi, N., Volik, S. V., Anderson, S. A., Haegert, A. M., McConeghy, B. J., Sar, F., Brahmbhatt, S., Bell, R. H., Bihan, S. L., et al. (2020) · Cancers · doi:10.3390/cancers12061568 · Cited by 45
Single-Cell View of Tumor Microenvironment Gradients in Pleural Mesothelioma
Giotti, B., Dolasia, K., Zhao, W. M., Cai, P., Sweeney, R. E., Merritt, E., Kiner, E., Kim, G. S., Bhagwat, A., Nguyen, T., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0017 · Cited by 44
Klebe, S., Nakatani, Y., Dobra, K., Butnor, K. J., Roden, A. C., Nicholson, A. G., Marchevsky, A. M., Husain, A. N., Segal, A., Walts, A. E., et al. (2021) · Pathology · doi:10.1016/j.pathol.2020.12.005 · Cited by 44
Self-citationYang, H., Hall, S. R. R., Sun, B., Zhao, L., Gao, Y., Schmid, R. A., Tan, S. T., Peng, R., & Yao, F. (2021) · Cancers · doi:10.3390/cancers13071561 · Cited by 44
NF2: An underestimated player in cancer metabolic reprogramming and tumor immunity
Xu, D., Yin, S., & Shu, Y. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00627-5 · Cited by 43
Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma
Yang, H., Xu, D., Schmid, R. A., & Peng, R. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920971421 · Cited by 43
Ho, K., Huang, T.-W., Shih, C.-M., Lee, Y.-T., Liu, A.-J., Chen, P., & Chen, K. (2021) · BMC Medicine · doi:10.1186/s12916-021-01925-6 · Cited by 43
Molecular characterization of localized pleural mesothelioma
Hung, Y. P., Dong, F., Dubuc, A. M., Cin, P. D., Bueno, R., & Chirieac, L. R. (2019) · Modern Pathology · doi:10.1038/s41379-019-0330-9 · Cited by 42
Self-citation
Metadata
- Authors
- Hmeljak, J., Sanchez-Vega, F., Hoadley, K. A., Shih, J., Stewart, C., Heiman, D., Tarpey, P., Danilova, L., Drill, E., Gibb, E. A., Bowlby, R., Kanchi, R., Osmanbeyoglu, H. U., Sekido, Y., Takeshita, J., Newton, Y., Graim, K., Gupta, M., Gay, C. M., Diao, L., Gibbs, D. L., Thorsson, V., Iype, L., Kantheti, H., Severson, D. T., Ravegnini, G., Desmeules, P., Jungbluth, A. A., Travis, W. D., Dacic, S., Chirieac, L. R., Galateau-Sallé, F., Fujimoto, J., Husain, A. N., Silveira, H. C., Rusch, V. W., Rintoul, R. C., Pass, H., Kindler, H., Zauderer, M. G., Kwiatkowski, D. J., Bueno, R., Tsao, A. S., Creaney, J., Lichtenberg, T., Leraas, K., Bowen, J., TCGA Research Network, Felau, I., Zenklusen, J. C., Akbani, R., Cherniack, A. D., Byers, L. A., Noble, M. S., Fletcher, J. A., Robertson, A. G., Shen, R., Aburatani, H., Robinson, B. W., Campbell, P., Ladanyi, M., Aburatani, H., Akbani, R., Ally, A., Anur, P., Armenia, J., Auman, J. T., Balasundaram, M., Balu, S., Baylin, S. B., Becich, M., Behrens, C., Beroukhim, R., Bielski, C., Bodenheimer, T., Bootwalla, M. S., Bowen, J., Bowlby, R., Brooks, D., Bueno, R., Byers, L. A., Cárcano, F. M., Carlsen, R., Carvalho, A. L., Cherniack, A. D., Cheung, D., Chirieac, L., Cho, J., Chuah, E., Chudamani, S., Cibulskis, C., Cope, L., Crain, D., Creaney, J., Curley, E., Dacic, S., Danilova, L., Rienzo, A. D., DeFreitas, T., Demchok, J. A., Dhalla, N., Dhir, R., Diao, L., Drill, E., Felau, I., Feldman, M., Ferguson, M. L., Fletcher, J. A., Fujimoto, J., Fujimoto, J., Fukuda, S., Gabriel, S. B., Sallé, F. G., Gao, J., Gardner, J., Gastier-Foster, J. M., Gay, C. M., Gehlenborg, N., Gerken, M., Getz, G., Gibb, E. A., Gibbs, D. L., Goparaju, C., Graim, K., Gross, B., Guo, G., Gupta, M., Hasegawa, S., Haussler, D., Hayes, D. N., Heiman, D. I., Heins, Z., Hmeljak, J., Hoadley, K. A., Holt, R. A., Hoyle, A. P., Husain, A., Hutter, C. M., Iype, L., Jefferys, S. R., Jones, S. J. M., Jones, C. D., Kanchi, R. S., Kasaian, K., Kim, J., Kindler, H., Kondo, N., Krausz, T., Kundra, R., Kuribayashi, K., Kwiatkowski, D. J., Ladanyi, M., Lai, P. H., Laird, P. W., Lawrence, M. S., Lee, D., Leraas, K. M., Lichtenberg, T. M., Lin, P., Liu, J., Liu, W., Liu, E. M., Lolla, L., Longatto-Filho, A., Lu, Y., Luketich, J., Ma, Y., Maglinte, D. T., Mallory, D., Marra, M. A., Mayo, M., Meier, S., Melamed, J., Meng, S., Meyerson, M., Mieczkowski, P. A., Mills, G. B., Moore, R. A., Moran, C., Morris, S., Mose, L. E., Mungall, A. J., Mungall, K., Nakano, T., Naresh, R., Newton, Y., Noble, M. S., Ochoa, A., Osmanbeyoglu, H., Parker, J. S., Pass, H. I., Paulauskis, J., Pennathur, A., Pennell, N. A., Penny, R., Perou, C. M., Pihl, T., Ramirez, N. C., Rassl, D. M., Ravegnini, G., Reid, G., Reis, R. M., Reynolds, S. M., Rice, D., Richards, W. G., Rintoul, R. C., Roach, J., Robertson, A. G., Rusch, V., Sadeghi, S., Saksena, G., Sanchez-Vega, F., Sander, C., Sato, A., Scapulatempo-Neto, C., Schein, J. E., Schultz, N., Schumacher, S. E., Seiwert, T., Sekido, Y., Severson, D. T., Shelton, C., Shelton, T., Shen, R., Sheridan, R., Shi, Y., Shih, J., Shiraishi, Y., Shmulevich, I., Silveira, H. C. S., Simons, J. V., Sipahimalani, P., Skelly, T., Sofia, H. J., Soloway, M. G., Spellman, P., Stewart, C., Stuart, J., Sun, Q., Takeshita, J., Tam, A., Tan, D., Tarnuzzer, R., Tatsuno, K., Taylor, B. S., Thiessen, N., Thompson, E., Thorsson, V., Travis, W. D., Tsao, A., Tse, K., Tsujimura, T., Valdivieso, F., Van Den Berg, D. J., van Zandwijk, N., Veluvolu, U., Viana, L. S., Voet, D., Wan, Y., Wang, Z., Wang, J., Weaver, J., Weinstein, J. N., Weisenberger, D. J., Wilkerson, M. D., Wise, L., Wistuba, I., Wong, T., Wu, Y., Yamamoto, S., Yang, L., Zauderer, M. G., Zenklusen, J. C., Zhang, J., Zhang, H., Zhang, H., & Zmuda, E.
- Affiliations
- 3Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
- Wellcome Sanger Institute (GB)
- 10Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- 11Computational Systems Biology, Memorial Sloan Kettering Cancer Center, New York, New York.
- The University of Texas at Dallas (US)
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- Memorial Sloan Kettering Cancer Center (US)
- 23Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
- 24MESOPATH. Cancer Center Leon Berard, Lyon, France.
- 26Department of Pathology, University of Chicago, Chicago, Illinois.
- 27Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil.
- 28Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
- 30Department of Cardiothoracic Surgery, NYU Langone Medical Center, New York, New York.
- 15Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- 35The Research Institute at Nationwide Children's Hospital, Columbus, Ohio.
- 36National Cancer Institute, Bethesda, Maryland.
- 18Division of Thoracic Surgery, The Lung Center and International Mesothelioma Program, Brigham and Women's Hospital, Boston, Massachusetts.
- The University of Western Australia (AU)
- ORCID
- Tarpey, Patrick
- Kantheti, Havish
- Desmeules, Patrice
- Jungbluth, Achim A.
- Silveira, Henrique C.
- Tsao, Anne S.
- Robinson, Bruce W.
- Campbell, Peter
- Armenia, Joshua
- Auman, J. Todd
- Baylin, Stephen B.
- Becich, Michael
- Behrens, Carmen
- Beroukhim, Rameen
- Bootwalla, Moiz S.
- Cibulskis, Carrie
- Cope, Leslie
- Rienzo, Assunta De
- Dhir, Rajiv
- Ferguson, Martin L.
- Fukuda, Shiro
- Gabriel, Stacey B.
- Gao, Jianjiong
- Gehlenborg, Nils
- Getz, Gad
- Goparaju, Chandra
- Gross, Benjamin
- Guo, Guangwu
- Hasegawa, Seiki
- Haussler, David
- Hayes, D. Neil
- Heins, Zachary
- Holt, Robert A.
- Hoyle, Alan P.
- Jefferys, Stuart R.
- Jones, Steven J.M.
- Jones, Corbin D.
- Kasaian, Katayoon
- Kim, Jaegil
- Kondo, Nobuyuki
- Kundra, Ritika
- Kuribayashi, Kozo
- Laird, Peter W.
- Lawrence, Michael S.
- Lee, Darlene
- Lin, Pei
- Liu, Jia
- Liu, Wenbin
- Liu, Eric Minwei
- Lu, Yiling
- Luketich, James
- Maglinte, Dennis T.
- Marra, Marco A.
- Mayo, Michael
- Melamed, Jonathan
- Meyerson, Matthew
- Mieczkowski, Piotr A.
- Mills, Gordon B.
- Mungall, Andrew J.
- Nakano, Takashi
- Ochoa, Angelica
- Parker, Joel S.
- Pennathur, Arjun
- Pennell, Nathan A.
- Perou, Charles M.
- Pihl, Todd
- Ramirez, Nilsa C.
- Rassl, Doris M.
- Reid, Glen
- Reis, Rui M.
- Rice, David
- Richards, William G
- Roach, Jeffrey
- Sadeghi, Sara
- Saksena, Gordon
- Sander, Chris
- Sato, Ayuko
- Schultz, Nikolaus
- Schumacher, Steven E.
- Seiwert, Tanguy
- Shi, Yan
- Shiraishi, Yuichi
- Sofia, Heidi J.
- Spellman, Paul
- Sun, Qiang
- Tam, Angela
- Tarnuzzer, Roy
- Tatsuno, Kenji
- Taylor, Barry S
- Tsujimura, Tohru
- Wang, Jing
- Weaver, Joellen
- Weinstein, John N.
- Weisenberger, Daniel J.
- Wilkerson, Matthew D.
- Wistuba, Ignacio
- Wong, Tina
- Wu, Ye
- Yamamoto, Shogo
- Yang, Liming
- Zhang, Jiashan
- Zhang, Hailei
- Zhang, Hongxin
- Zmuda, Erik
- Venue
- Cancer Discovery
- Published
- 2018-12-01
- Volume
- 8
- Issue
- 12
- Pages
- 1548-1565
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6310008
- OpenAlex
- W2897299514
- Cited by
- 618
- References
- 62
- Citations by year
- 2026: 53 · 2025: 62 · 2024: 61 · 2023: 78 · 2022: 96 · 2021: 117 · 2020: 100 · 2019: 45 · 2018: 4
- FWCI
- 50.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
- Funders
- HHS | National Institutes of Health (NIH) (U54 HG003273, U24 CA143858, U24 CA143866, U24 CA143867, U24 CA143882, U24 CA143883, U24 CA144025, P30 CA016672, P30 CA008748, U54 HG003067, U54 HG003079, U24 CA143799, U24 CA143835, U24 CA143840, U24 CA143843, U24 CA143845, U24 CA143848)
- British Lung Foundation (BLF) (APG11-7)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- malignant pleural mesothelioma, TP53 mutation, loss of heterozygosity, genomic subtypes, VISTA, immune checkpoint, epithelioid mesothelioma, immunotherapy, antitumor immunity
- MeSH terms
- Aged, Female, Humans, Lung Neoplasms, Male, Mesothelioma, Middle Aged, Mutation, Pleural Neoplasms, Prognosis, Histone-Lysine N-Methyltransferase, Protein Methyltransferases, Biomarkers, Tumor, Tumor Suppressor Proteins, Ubiquitin Thiolesterase, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.